Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Pexastimogene devacirepvec by Sillajen Biotherapeutics for Renal Cell Carcinoma: Likelihood of Approval
Pexastimogene devacirepvec is under clinical development by Sillajen Biotherapeutics and currently in Phase III for Renal Cell Carcinoma. According to...
Data Insights
Pexastimogene devacirepvec by Sillajen Biotherapeutics for Prostate Cancer: Likelihood of Approval
Pexastimogene devacirepvec is under clinical development by Sillajen Biotherapeutics and currently in Phase II for Prostate Cancer. According to GlobalData,...